Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant:Lead identification and SAR of 3-and 4-substituted derivatives
Mj. Genin et al., Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant:Lead identification and SAR of 3-and 4-substituted derivatives, J MED CHEM, 43(5), 2000, pp. 1034-1040
Through computationally directed broad screening, a novel 1,5-diphenylpyraz
ole (DPP) class of HIV-1 nonnucleoside reverse transcriptase inhibitors (NN
RTIs) has been discovered. Compound 2 (PNU-32945) was found to have good ac
tivity versus wild-type (IC50 = 2.3 mu M) and delavirdine-resistant P236L (
IC50 = 1.1 mu M) reverse transcriptase IRT). Also, PNU-32945 has an ED50 fo
r inhibition of viral replication in cell cultures of 0.1 mu M and was show
n to be noncytotoxic with a CC50 > 10 mu M. Structure-activity relationship
studies on the 3- and 4-positions of PNU-32945 led to interesting selectiv
ity and activity within the class. In particular, the 3-hydroxyethyl-4-ethy
l congener 29 is a potent inhibitor of the P236L mutant (IC50 = 0.65 mu M),
whereas it is essentially inactive versus the wild-type enzyme (IC50 > 50
mu M). Furthermore, this compound was significantly more active versus the
P236L mutant than delavirdine. The synthesis and RT inhibitory activity of
various 3- and 4-substituted analogues are discussed.